Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
PLoS One
2016 Jan 01;112:e0148129. doi: 10.1371/journal.pone.0148129.
Show Gene links
Show Anatomy links
MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit.
Volkmann RA
,
Fanger CM
,
Anderson DR
,
Sirivolu VR
,
Paschetto K
,
Gordon E
,
Virginio C
,
Gleyzes M
,
Buisson B
,
Steidl E
,
Mierau SB
,
Fagiolini M
,
Menniti FS
.
???displayArticle.abstract???
GluN2A is the most abundant of the GluN2 NMDA receptor subunits in the mammalian CNS. Physiological and genetic evidence implicate GluN2A-containing receptors in susceptibility to autism, schizophrenia, childhood epilepsy and neurodevelopmental disorders such as Rett Syndrome. However, GluN2A-selective pharmacological probes to explore the therapeutic potential of targeting these receptors have been lacking. Here we disclose a novel series of pyrazine-containing GluN2A antagonists exemplified by MPX-004 (5-(((3-chloro-4-fluorophenyl)sulfonamido)methyl)-N-((2-methylthiazol-5-yl)methyl)pyrazine-2-carboxamide) and MPX-007 (5-(((3-fluoro-4-fluorophenyl)sulfonamido)methyl)-N-((2-methylthiazol-5-yl)methyl)methylpyrazine-2-carboxamide). MPX-004 and MPX-007 inhibit GluN2A-containing NMDA receptors expressed in HEK cells with IC50s of 79 nM and 27 nM, respectively. In contrast, at concentrations that completely inhibited GluN2A activity these compounds have no inhibitory effect on GluN2B or GluN2D receptor-mediated responses in similar HEK cell-based assays. Potency and selectivity were confirmed in electrophysiology assays in Xenopus oocytes expressing GluN2A-D receptor subtypes. Maximal concentrations of MPX-004 and MPX-007 inhibited ~30% of the whole-cell current in rat pyramidal neurons in primary culture and MPX-004 inhibited ~60% of the total NMDA receptor-mediated EPSP in rat hippocampal slices. GluN2A-selectivity at native receptors was confirmed by the finding that MPX-004 had no inhibitory effect on NMDA receptor mediated synaptic currents in cortical slices from GRIN2A knock out mice. Thus, MPX-004 and MPX-007 offer highly selective pharmacological tools to probe GluN2A physiology and involvement in neuropsychiatric and developmental disorders.
???displayArticle.pubmedLink???
26829109
???displayArticle.pmcLink???PMC4734667 ???displayArticle.link???PLoS One
Fig 1. The structures of TCN-201, MPX-004 and MPX-007.The values are IC50s for inhibition of Ca2+ responses mediated by GluN2A receptors expressed in HEK cells.
Fig 2. Concentration-response of TCN-201, MPX-004, and MPX-007 inhibition of Ca2+ responses mediated by GluN2A expressed in HEK cells.Cells were stimulated with glutamate and glycine (3 μM each) in the presence of compounds at a range of concentrations. Curves for inhibition of the Ca2+ response in GluN2A-expressing cells were derived from fits to the Hill equation using GraphPad Prism (v6.00 for Mac, GraphPad Software, La Jolla California USA). Whereas MPX-004 and MPX-007 achieve full inhibition of the GluN2A Ca2+ response by ~ 3 μM, TCN-201 never inhibits more than ~40% of the response. Each data point is a mean (± standard deviation) of data from 20â86 experiments).
Fig 3. Potency or efficacy of TCN-201 and selected analogs for inhibition of Ca2+ responses mediated by GluN2A, GluN2B and GluN2D expressed in HEK cells.Cells were stimulated with glutamate and glycine (3 μM each) in the presence of compounds at a range of concentrations. IC50 for inhibition of the Ca2+ response in GluN2A-expressing cells was fitted to the Hill equation using CDD Vault. For GluN2B or GluN2D no IC50 could be determined, so the effect of each compound at 10 μM is shown as the % inhibition of the Ca2+ response (note that negative % inhibition represents an increase in Ca2+ response over glutamate plus glycine alone). Values are the mean IC50 or % ± SEM with the number of replicate curves indicated in parentheses. ND- not determined.
Fig 4. Effect of MPX-004 and MPX-007 on glutamate/glycine-induced currents in Xenopus oocytes expressing GluN1 and GluN2A, B, C, or D.Oocytes were exposed to MPX-004 or MPX-007 at concentrations from 10 nM to 10 μM as indicated. Inhibition curves were generated using GraphPad Prism and IC50 values were generated using CCD Vault. The IC50s for inhibition of GluN2A-mediated currents were 198 ± 17 and 143 ± 10 nM for MPX-004 and MPX-007, respectively. Each data point is a mean (± standard deviation) of data from 4â12 oocytes.
Fig 5. Effects of MPX-004 and MPX-007 on NMDA/glycine-induced currents of rat cortical neurons in primary culture.Cortical neurons were maintained in primary culture for 13â15 days and then examined using whole-cell manual patch clamp for current evoked by NMDA (100 μM) + glycine (10 μM) applied for 4 seconds during 10 second pulses to +20 or +40 mV from a holding potential of -70 mV. Inhibition of NMDA-activated currents was quantified during exposure to 10 μM MPX-007, MPX-004, Ro 25â6981, or a combination of Ro 25â6981 + MPX-004. Currents were blocked ~25â30% by either MPX-007 or MPX-004 alone, ~70% by Ro 25â6981 alone, and ~85% by Ro 25â6981 plus MPX-004.
Fig 6. Effect of MPX-004 on isolated NMDA receptor-mediated fEPSPs in rat hippocampal CA1 stratum radiatum in response to stimulation of Schaffer collateral input.Slices were exposed to MPX-004 from 100 nM to 30 μM in half log concentration increments as well as to 50 μM. Right panel- Time course for inhibition of fEPSPs after application of different concentrations of MPX-004. Left panel- Percent inhibition at 40 min after application for each MPX-004 concentration. Maximum inhibition was approximately 60% of the fEPSPs at 30 or 50 μM. The IC50 of MPX-004 for inhibition of fEPSPs was 3.4 μM. Curves in the right panel and data point in the left panel are a mean (± SEM) of 4, 5, 6, 8, 6, 5 and 2 slices obtained from 2, 2, 3, 3, 2, 2 and 1 rats exposed to 0.1, 0.3, 1, 3, 10, 30 and 50 μM MPX-004, respectively. In separate experiments, a highly selective GluN2B NAM inhibited approximately 40% of the fEPSP (data not shown).
,
Correction: MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit.
2016, Pubmed
,
Correction: MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit.
2016,
Pubmed
Barnby,
Candidate-gene screening and association analysis at the autism-susceptibility locus on chromosome 16p: evidence of association at GRIN2A and ABAT.
2005,
Pubmed
Ben-Ari,
GABAA, NMDA and AMPA receptors: a developmentally regulated 'ménage à trois'.
1997,
Pubmed
Bettini,
Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors.
2010,
Pubmed
Carvill,
GRIN2A mutations cause epilepsy-aphasia spectrum disorders.
2013,
Pubmed
Chenard,
Antagonists selective for NMDA receptors containing the NR2B subunit.
1999,
Pubmed
Collingridge,
Memories of NMDA receptors and LTP.
1995,
Pubmed
Conn,
Pharmacology and functions of metabotropic glutamate receptors.
1997,
Pubmed
Cull-Candy,
Role of distinct NMDA receptor subtypes at central synapses.
2004,
Pubmed
Cull-Candy,
NMDA receptor subunits: diversity, development and disease.
2001,
Pubmed
Dupuis,
Effect of beta-adrenoceptor blockers on human ether-a-go-go-related gene (HERG) potassium channels.
2005,
Pubmed
,
Xenbase
Durand,
NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2.
2012,
Pubmed
Edman,
TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner.
2012,
Pubmed
,
Xenbase
Endele,
Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes.
2010,
Pubmed
Fagiolini,
Separable features of visual cortical plasticity revealed by N-methyl-D-aspartate receptor 2A signaling.
2003,
Pubmed
Fischer,
Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro.
1997,
Pubmed
,
Xenbase
Fromer,
De novo mutations in schizophrenia implicate synaptic networks.
2014,
Pubmed
Gambrill,
NMDA receptor subunit composition controls synaptogenesis and synapse stabilization.
2011,
Pubmed
Gardoni,
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias.
2012,
Pubmed
Gipson,
Reinstatement of nicotine seeking is mediated by glutamatergic plasticity.
2013,
Pubmed
Greenwood,
Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia.
2011,
Pubmed
Hallett,
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
2005,
Pubmed
Hansen,
Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists.
2010,
Pubmed
,
Xenbase
Hansen,
Subunit-selective allosteric inhibition of glycine binding to NMDA receptors.
2012,
Pubmed
Hansen,
Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors.
2014,
Pubmed
,
Xenbase
Ishii,
Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits.
1993,
Pubmed
,
Xenbase
Kantrowitz,
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?
2010,
Pubmed
Karakas,
Crystal structure of a heterotetrameric NMDA receptor ion channel.
2014,
Pubmed
Kew,
Ionotropic and metabotropic glutamate receptor structure and pharmacology.
2005,
Pubmed
Krystal,
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.
2003,
Pubmed
Layton,
Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists.
2006,
Pubmed
Lee,
NMDA receptor structures reveal subunit arrangement and pore architecture.
2014,
Pubmed
,
Xenbase
Lee,
Metaplasticity at single glutamatergic synapses.
2010,
Pubmed
Lemke,
Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes.
2013,
Pubmed
,
Xenbase
Lesca,
GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction.
2013,
Pubmed
Mierau,
Cell-Specific Regulation of N-Methyl-D-Aspartate Receptor Maturation by Mecp2 in Cortical Circuits.
2016,
Pubmed
Monaghan,
Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators.
2012,
Pubmed
Monyer,
Developmental and regional expression in the rat brain and functional properties of four NMDA receptors.
1994,
Pubmed
Ogden,
New advances in NMDA receptor pharmacology.
2011,
Pubmed
Olney,
NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia.
1995,
Pubmed
Paoletti,
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease.
2013,
Pubmed
Philpot,
Obligatory role of NR2A for metaplasticity in visual cortex.
2007,
Pubmed
Quinlan,
Bidirectional, experience-dependent regulation of N-methyl-D-aspartate receptor subunit composition in the rat visual cortex during postnatal development.
1999,
Pubmed
Rauner,
Triheteromeric NR1/NR2A/NR2B receptors constitute the major N-methyl-D-aspartate receptor population in adult hippocampal synapses.
2011,
Pubmed
Sheng,
Changing subunit composition of heteromeric NMDA receptors during development of rat cortex.
1994,
Pubmed
Shepherd,
The cell biology of synaptic plasticity: AMPA receptor trafficking.
2007,
Pubmed
Soares,
A prominent role for triheteromeric GluN1/GluN2A/GluN2B NMDARs at central synapses.
2013,
Pubmed
Standaert,
Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat.
1994,
Pubmed
Steidl,
The adult rat hippocampal slice revisited with multi-electrode arrays.
2006,
Pubmed
Stocca,
Increased contribution of NR2A subunit to synaptic NMDA receptors in developing rat cortical neurons.
1998,
Pubmed
Tovar,
Triheteromeric NMDA receptors at hippocampal synapses.
2013,
Pubmed
Traynelis,
Glutamate receptor ion channels: structure, regulation, and function.
2010,
Pubmed
Wu,
Tissue-type plasminogen activator protects neurons from excitotoxin-induced cell death via activation of the ERK1/2-CREB-ATF3 signaling pathway.
2013,
Pubmed
Yashiro,
Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity.
2008,
Pubmed
Yuan,
Control of NMDA receptor function by the NR2 subunit amino-terminal domain.
2009,
Pubmed
,
Xenbase
Zhou,
NMDA receptors in nervous system diseases.
2013,
Pubmed